Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.

NCT06720701 · clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
125
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna